<sentence id="0">Pentoxifylline for the treatment of infection with human immunodeficiency virus .</sentence>
<sentence id="1">Cytokine dysregulation in human immunodeficiency virus type 1 ( HIV-1 ) infection has been documented in numerous studies and has been cited as an important component in the pathogenesis of this retroviral infection .</sentence>
<sentence id="2"><scope type="spec" id="0"> Pharmacological modification of cytokine dysregulation , therefore , has been <cue type="spec" id="0">suggested</cue> as a therapeutic modality for HIV-1 infection</scope> .</sentence>
<sentence id="3">Dr. Dezube of Beth Israel Hospital ( Boston ) concisely reviews the state of our knowledge regarding the effects of pentoxifylline on expression of tumor necrosis factor-alpha , a cytokine known to influence HIV-1 replication and to play a <scope type="spec" id="1"> <cue type="spec" id="1">possible</cue> role in the clinical manifestations of advanced infection with this virus</scope> .</sentence>
<sentence id="4">Pentoxifylline , a trisubstituted xanthine derivative , has been used to decrease blood viscosity and is reasonably well tolerated by most recipients of the drug .</sentence>
<sentence id="5">Results of preliminary studies , many of which were conducted by Dr. Dezube , <scope type="spec" id="2"> <cue type="spec" id="2">suggest</cue> that use of this agent in combination with antiretroviral compounds <scope type="spec" id="3"> <cue type="spec" id="3">may</cue> prove useful in the treatment of patients with HIV-1 infection</scope></scope> .</sentence>